Healer

DECEMBER 17, 2021

Studies have shown CBD to be a safe substance, but as with any new drug, you must make sure it doesn’t negatively interact with other medications. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance. Most often, CBD interacts with other drugs via liver metabolism. By Dr. Dustin Sulak.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

SEPTEMBER 9, 2021

MyMD to highlight its development pipeline for MYMD-1, an immunometabolic regulator, and Supera-CBD, a synthetic cannabidiol derivative. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. During this presentation, Chris Chapman, M.D.,

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Puff Puff Post

JULY 8, 2019

Canna Research Group aimed to expand this traditional scope of cannabis research to include patterns of use and positive and adverse effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) in community-based adult athletes. When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist.

Chronic Pain 109

Chronic Pain Research and Development Clinical Trials THC 109

Puff Puff Post

JULY 8, 2019

Canna Research Group aimed to expand this traditional scope of cannabis research to include patterns of use and positive and adverse effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) in community-based adult athletes. When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist.

Chronic Pain 108

Chronic Pain Research and Development Clinical Trials THC 108

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. CBD PROMOTES BONE GROWTH. CBD alone is sufficiently effective in enhancing fracture healing.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Leaf Science

AUGUST 15, 2019

CBD products are taking the world by storm. CBD is non-psychoactive and is now making it into a wider variety of products such as those in the beauty arena and even making it into some fast food offerings like the ubiquitous cheeseburger. Now those supplements might very well contain CBD extract. So many options.

CBD 77

CBD Wellness and Beauty Tincture Clinical Trials 77

The Joint Blog

APRIL 21, 2020

The oral administration of purified CBD is associated with anxiolytic and anti-psychotic activity while possessing few adverts side-effects. This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. The search terms used were related to cannabis and CBD in adults.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. For more information, visit www.mymd.com. 616–623.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Otherside Farms

JULY 8, 2020

The healthcare industry is seeing significant investments in clinical trials to prove the health benefits of cannabis. Athletes go through intense training regularly to stay in perfect shape and prepare for competitive events. Sometimes the pressure could influence their ability to perform during competitive events intensely.

Marijuana 105

Marijuana Sleep Clinical Trials Events 105

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences. Christopher M. Chipman, CPA.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

JULY 27, 2021

and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 7, 2021

Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. blocking drugs, and aging and longevity. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

TheAnswerPage

MARCH 11, 2022

In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported. ” Kirkland AE, Fadus MC et al. Psych Resear. 308 (2022). See the Answer.

Clinical Trials 40

Clinical Trials Epilepsy Events Sleep 40

MMJ Recs

JULY 3, 2024

Cannabidiol (CBD) offers a natural alternative for those seeking relief from the symptoms of anxiety and stress. CBD, derived from the cannabis plant, has garnered attention for its potential therapeutic properties without the psychoactive effects commonly associated with tetrahydrocannabinol (THC). What is CBD?

CBD 52

CBD Research and Development Clinical Trials THC 52

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, in some cases, the risks may outweigh even the proven benefits.

Events 48

Events THC Chronic Pain Conditions 48

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical industry continues to expand. Del Morgan & Co.

Pharmaceutical 63

Pharmaceutical Clinical Trials Research and Development Events 63

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2

Treatment 52

Treatment Research and Development CBD Clinical Trials 52

Cannabis Law Report

JULY 7, 2021

Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. blocking drugs, and aging and longevity. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

AUGUST 26, 2022

The desire to understand the role of CBD in the body has never been greater. CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. Besides these, CBD has also been shown to contain antipsychotic properties that can neutralize the effects of tetrahydrocannabinol found in cannabis.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

LifeCannMD

MAY 27, 2025

Now, with 1.5mg of a balanced THC:CBD tincture twice daily, he’s giving presentations at work and actually enjoying social events again. After six months of microdosing marijuana (2mg THC + 2mg CBD twice daily), his pain went from an 8/10 to a 3/10, and he’s back to playing golf three times a week.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 40

Clinical Trials Events Therapy Sleep 40

Cannabis Law Report

OCTOBER 17, 2019

(Tree of Knowledge) (CSE:TOKI) (OTC:TOKIF) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

SEPTEMBER 22, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. Watch how Supera-CBD works. “We Chief Scientific Officer of MyMD. “We

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Healer

DECEMBER 17, 2021

Studies have shown CBD to be a safe substance, but as with any new drug, you must make sure it doesn’t negatively interact with other medications. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance. Most often, CBD interacts with other drugs via liver metabolism. By Dr. Dustin Sulak.

CBD 52

CBD THC Conditions Medicine 52

MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. Key cannabinoids include tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), each exerting unique effects on the ECS and potentially influencing sleep patterns. Acute insomnia usually lasts for a few days to a few weeks.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

OCTOBER 5, 2021

will discuss the Company’s product pipeline with diversified indications for MYMD-1 as an immunometabolic regulator and Supera-CBD as a synthetic CBD derivative. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. and Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

OCTOBER 19, 2021

will discuss the multiple indications for each of MyMD’s novel drug candidates, MYMD-1 and Supera-CBD. MyMD expects to launch two Phase 2 trials during the current quarter for MYMD-1 – one for delaying aging and prolonging healthy lifespan, and the other for post- COVID-19 depression and cytokine elevation. About Supera-CBD.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. For more information, visit www.mymd.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

DECEMBER 1, 2021

MyMD to highlight its development pipeline for two novel therapeutics: immune regulator MYMD-1 and synthetic cannabidiol derivative Supera-CBD. During the conferences, MyMD executives will discuss the multiple indications being pursued and market opportunities for novel drug candidates MYMD-1 and Supera-CBD. About Supera-CBD.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.

Clinical Trials 40

Clinical Trials Research and Development Sleep Cannabinoids 40